Literature DB >> 2204382

Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

P A Andrews1, S B Howell.   

Abstract

The interactions of cisplatin with DNA have been defined in sophisticated detail; however, the interactions of this drug with other components of the cell are less well understood. There is much interest in how cisplatin gets into cells, how it is transformed and inactivated, how it and its biotransformation products are effluxed from the cell, how the DNA damage is repaired, and how all of these processes can be modulated for therapeutic gain. Recent years have seen much progress toward defining the cellular pharmacology of cisplatin and, in the process, several mechanisms of acquired resistance to this drug have now been elucidated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204382

Source DB:  PubMed          Journal:  Cancer Cells        ISSN: 1042-2196


  113 in total

Review 1.  Overcoming drug resistance in ovarian carcinoma.

Authors:  P M Fracasso
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Cytoplasmic initiation of cisplatin cytotoxicity.

Authors:  Fang Yu; Judit Megyesi; Peter M Price
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-09

Review 3.  New roles for copper metabolism in cell proliferation, signaling, and disease.

Authors:  Michelle L Turski; Dennis J Thiele
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

4.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.

Authors:  M Yamada; E O'Regan; R Brown; P Karran
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

5.  Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.

Authors:  J G Moggs; D E Szymkowski; M Yamada; P Karran; R D Wood
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

6.  Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Authors:  Kalpana Mujoo; Masayuki Watanabe; Junichi Nakamura; Abdul R Khokhar; Zahid H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

7.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

Authors:  X Wu; Z Fan; H Masui; N Rosen; J Mendelsohn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

Authors:  R D Christen; A P Jekunen; J A Jones; F Thiebaut; D R Shalinsky; S B Howell
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.

Authors:  W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.